8-KMaterial AgreementsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Jan 29, 2010)

Filed January 29, 2010For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) announced on January 28, 2010, its entry into an accelerated share repurchase agreement (ASR) with Barclays Bank PLC for approximately $250 million of its common stock. This transaction is part of the company's ongoing stock repurchase program, signaling a commitment to returning capital to shareholders and potentially boosting the stock price. Under the terms, Quest Diagnostics will receive an initial delivery of 4,460,304 shares on January 29, 2010, at a fixed price of $56.05 per share. The final number of shares repurchased will be determined by the volume-weighted average price over a subsequent four-to-eight-week period, with adjustments for the company to either receive additional shares or pay cash/issue more shares. This structure allows for flexibility and aims to execute the repurchase efficiently at a market-driven price.

Key Highlights

  • 1Quest Diagnostics entered into an accelerated share repurchase (ASR) agreement valued at approximately $250 million.
  • 2The ASR agreement is part of the company's existing common stock repurchase program.
  • 3Barclays Bank PLC will deliver an initial 4,460,304 shares on January 29, 2010.
  • 4The initial repurchase price is set at $56.05 per share.
  • 5The final number of shares repurchased will be based on a volume-weighted average price over a 4-8 week measurement period.
  • 6The company may receive additional shares or be required to remit cash/additional shares based on the final average price.
  • 7This move indicates management's confidence in the company's stock and its commitment to shareholder returns.

Frequently Asked Questions

An ASR agreement is a transaction where a company buys back its own stock from a bank or financial institution. The company typically receives a substantial portion of the shares immediately, with the final number of shares repurchased determined later based on the average market price over a specified period. This allows for efficient execution of large buybacks.

Quest Diagnostics is repurchasing its stock as part of its ongoing common stock repurchase program. This action typically signals that the company believes its stock is undervalued, aims to increase shareholder value by reducing the number of outstanding shares, and may indicate management's confidence in future earnings and growth.

Share repurchases, especially significant ones like this $250 million ASR, tend to be viewed positively by investors. They reduce the supply of outstanding shares, which can increase earnings per share (EPS) and potentially drive up the stock price. It also demonstrates the company's financial health and commitment to returning capital to shareholders.

The final number of shares will be determined by the arithmetic average of the daily volume-weighted average price of Quest Diagnostics' common stock over a measurement period of approximately four to eight weeks. After this period, Quest Diagnostics may receive additional shares if the average price was lower than the initial repurchase price, or it may need to pay cash or issue more shares if the average price was higher.